Teachers Retirement System of The State of Kentucky Trims Position in Bristol-Myers Squibb (NYSE:BMY)

Teachers Retirement System of The State of Kentucky reduced its position in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 4.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 265,482 shares of the biopharmaceutical company's stock after selling 13,426 shares during the period. Teachers Retirement System of The State of Kentucky's holdings in Bristol-Myers Squibb were worth $15,015,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Wealthspire Advisors LLC grew its stake in shares of Bristol-Myers Squibb by 0.6% in the 4th quarter. Wealthspire Advisors LLC now owns 28,679 shares of the biopharmaceutical company's stock worth $1,622,000 after buying an additional 170 shares in the last quarter. Edmp Inc. grew its position in Bristol-Myers Squibb by 0.4% in the fourth quarter. Edmp Inc. now owns 41,599 shares of the biopharmaceutical company's stock worth $2,353,000 after acquiring an additional 171 shares in the last quarter. Trust Point Inc. increased its stake in Bristol-Myers Squibb by 1.9% during the fourth quarter. Trust Point Inc. now owns 9,423 shares of the biopharmaceutical company's stock worth $533,000 after acquiring an additional 172 shares during the last quarter. Bedel Financial Consulting Inc. raised its position in Bristol-Myers Squibb by 3.2% during the fourth quarter. Bedel Financial Consulting Inc. now owns 5,690 shares of the biopharmaceutical company's stock valued at $340,000 after purchasing an additional 175 shares during the period. Finally, Horst & Graben Wealth Management LLC lifted its stake in shares of Bristol-Myers Squibb by 2.4% in the 4th quarter. Horst & Graben Wealth Management LLC now owns 7,538 shares of the biopharmaceutical company's stock valued at $426,000 after purchasing an additional 179 shares during the last quarter. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Bristol-Myers Squibb Stock Down 1.7 %

Bristol-Myers Squibb stock traded down $0.83 during trading hours on Friday, reaching $47.86. The stock had a trading volume of 16,292,011 shares, compared to its average volume of 12,961,714. Bristol-Myers Squibb has a 52 week low of $39.35 and a 52 week high of $63.33. The company has a market cap of $97.38 billion, a price-to-earnings ratio of -10.83, a PEG ratio of 2.07 and a beta of 0.41. The company has a debt-to-equity ratio of 2.90, a current ratio of 1.25 and a quick ratio of 1.15. The business's 50 day moving average price is $56.37 and its 200-day moving average price is $56.47.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last posted its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, beating analysts' consensus estimates of $1.55 by $0.25. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The company had revenue of $11.20 billion during the quarter, compared to analysts' expectations of $10.77 billion. During the same quarter in the prior year, the company posted ($4.40) earnings per share. Sell-side analysts anticipate that Bristol-Myers Squibb will post 6.74 EPS for the current year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, May 1st. Investors of record on Friday, April 4th will be given a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a yield of 5.18%. The ex-dividend date is Friday, April 4th. Bristol-Myers Squibb's dividend payout ratio is currently 92.88%.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. Citigroup raised their price target on Bristol-Myers Squibb from $60.00 to $65.00 and gave the stock a "neutral" rating in a research report on Tuesday, January 28th. Truist Financial lifted their price target on shares of Bristol-Myers Squibb from $62.00 to $65.00 and gave the stock a "buy" rating in a research note on Wednesday, January 8th. Wells Fargo & Company boosted their target price on Bristol-Myers Squibb from $60.00 to $62.00 and gave the company an "equal weight" rating in a research report on Friday, February 7th. Cantor Fitzgerald restated a "neutral" rating and set a $55.00 price objective on shares of Bristol-Myers Squibb in a report on Tuesday. Finally, Jefferies Financial Group reduced their target price on Bristol-Myers Squibb from $70.00 to $68.00 and set a "buy" rating on the stock in a research note on Wednesday. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating, five have issued a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $58.00.

Insider Buying and Selling at Bristol-Myers Squibb

In related news, EVP Samit Hirawat acquired 1,823 shares of the company's stock in a transaction dated Friday, February 14th. The shares were purchased at an average cost of $54.84 per share, with a total value of $99,973.32. Following the completion of the acquisition, the executive vice president now directly owns 63,932 shares of the company's stock, valued at $3,506,030.88. This represents a 2.94 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.09% of the stock is currently owned by company insiders.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.